[Trust-based economics with medicine outcome-based pricing].
In recent decades, the pharmaceutical industry as built a high level of confidence thanks to innovative medicines that improve both duration and quality of life. Some recent scandals have however discredited this industry, now suspected of cheating or bribery. Even the scientific progresses are challenged on the ground of possible conflicts of interests and value uncertainty. This situation is deleterious. Simultaneously the economic crisis exacerbates the payers' expectations in terms of clinical value and value/price ratio. It also stimulates the demand for outcomes in real life. This induces a new economic approach for the market access of highly expensive reimbursable drugs. It consists in paying only for drugs actually proven effective in terms of actual outcomes, with a full or partial refund of the payer in case of failure, according to accurate and simple criteria in so called "performance agreement". Confidence is restored accordingly.
Université Paris Descartes, 12, rue de l'École-de-Médecine, 75006 Paris, France; CEPS, ministère des affaires sociales et de la santé, 14, avenue Duquesne, 75350 Paris 07 SP, France. Electronic address: francois.lhoste@finances.gouv.fr.
F
F
Lhoste
D003363:Cost Control / Q000191:economics; D003365:Costs and Cost Analysis / Q000639:trends*; D004345:Drug Industry / Q000193:education / Q000639:trends; D004358:Drug Therapy / Q000191:economics* / Q000639:trends; D006801:Humans; D016896:Treatment Outcome
Accès au marché; Agreement; Contrats; Innovation; Market access; Medicine; Médicament; Performance; Pricing; Prix; Valeur; Value